Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Multiple Sclerosis, Relapsing-Remitting

• Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
• Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
• Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
• RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
• A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis
• Study of IMCY-0141 in Recent Onset of Multiple Sclerosis
• Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
• B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
• Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
• Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
• Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects
• CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Thera
• A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis
• A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
• Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis
• Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial
• Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
• Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis
• A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
• Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
• Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
• Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
• Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
• Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
• Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
• Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).
• Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
• Phase II Clinical Trial of OCH-NCNP1
• Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis
• A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
• A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
• A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab
• Study of Evobrutinib in Participants With RMS
• Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
• Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
• 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.
• RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS
• Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
• TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
• Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
• MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
• Vaginal Estriol in Multiple Sclerosis
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV N
• Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis
• Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
• Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
• Melatonin in Patients With Multiple Sclerosis (MS).
• RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS
• A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)
• Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis
• Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
• Maximizing Outcome of Multiple Sclerosis Transplantation
• Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
• A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS
• Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
• Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
• Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
• Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)
• A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
• Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
• A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
• Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
• Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
• Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate
• Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
• Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®
• Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
• Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
• RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
• Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
• Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
• TMP001 in Relapsing-remitting Multiple Sclerosis
• Clinical Disease Activity With Long Term Natalizumab Treatment
• Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
• Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
• This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
• Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
• Plegridy Satisfaction Study in Participants
• Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
• Effect of Fingolimod on Neurodegeneration
• Brimonidine Tartrate for the Treatment of Injection Related Erythema
• Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
• A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
• Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
• Phase I BP Interferon (IFN) Beta-004
• Phase I BP Interferon (IFN) Beta-001
• Open-label Study of Liothyronine in MS
• Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
• Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
• Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)
• Teriflunomide Observational Effectiveness Study
• Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
• Tecfidera and the Gut Microbiota
• Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
• Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
• Oral Guanabenz for Multiple Sclerosis
• Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
• Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
• An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
• Fingolimod Effect on Cytokine and Chemokine Levels
• Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
• Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
• Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
• Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
• ACTH for Fatigue in Multiple Sclerosis Patients
• Comparative Oral Bioavailability Study of MT-1303
• Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
• Imaging of Intracerebral Inflammation in MS
• Mass Balance Study of MT-1303
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
• Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)
• Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
• Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
• BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
• Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
• Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS
• Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation
• Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
• Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
• A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
• Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
• Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
• Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
• Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
• Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
• A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
• Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
• A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
• A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
• Safety and Efficacy of Fingolimod in MS Patients in China
• Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
• A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
• A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
• Extension Study of MT-1303
• Safety and Tolerability of Glatiramer Acetate
• An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
• Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.
• A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
• Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
• Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
• Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
• Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
• Dose-finding Study of MT-1303
• Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).
• Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
• Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
• The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
• Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis
• Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
• ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
• NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
• STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
• An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
• Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
• Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
• Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
• Vitamin D Supplementation in Multiple Sclerosis
• Efficacy and Safety of GTR in Comparison to Copaxone®
• A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
• Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
• An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
• Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
• Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)
• Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
• Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
• A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
• Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
• A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
• Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.
• Fingolimod -Response According to Coping - Evaluation
• Impact of Vitamin A on Multiple Sclerosis (MS)
• Healthy Volunteer Study Using 3 Different Formulations of Firategrast
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
• Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
• Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
• Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
• Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients
• Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
• Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
• Advanced MRI Measures of Repair in Alemtuzumab Treated Patients
• Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
• Melatonin in Relapsing-Remitting Multiple Sclerosis Patients
• Vitamin D Pilot Study in Patients With Multiple Sclerosis
• Safety Study of BIIB033 in Subjects With Multiple Sclerosis
• Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
• Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
• Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
• Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
• Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis
• BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
• Natalizumab De-escalation With Interferon Beta-1b
• An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
• A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
• A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
• An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
• Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
• A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
• Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b
• Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
• Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
• A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
• Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
• Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
• Study on Cognitive Disorders of Multiple Sclerosis
• QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
• Treatment Interruption of Natalizumab
• A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
• POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
• Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
• A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
• Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
• Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
• Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)
• Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses
• Safety of New Formulation of Glatiramer Acetate
• Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b
• High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
• Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
• The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
• Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
• Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
• A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
• A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis
• A Study for Patients With Relapsing Remitting Multiple Sclerosis
• A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
• A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
• Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
• Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
• Rehabilitation Study in MS Patients
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
• An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
• A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
• Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo
• Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
• CLARITY Extension Study
• Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
• Flupirtine as Oral Treatment in Multiple Sclerosis
• Atorvastatin in Relapsing-Remitting Multiple Sclerosis
• Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)
• How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
• Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
• Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
• Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
• Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
• Tysabri Observational Program
• Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
• Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
• Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
• Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
• BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
• A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
• A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
• Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis
• RNF and Betaseron® Tolerability Study
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
• Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
• An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
• Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
• fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
• Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
• BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
• Omega-3 Fatty Acid Treatment in Multiple Sclerosis
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
• A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
• Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
• Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
• Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
• Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
• A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
• Natalizumab (Tysabri) Re-Initiation of Dosing
• A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
• High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
• Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis
• FOCUS Fatigue Outcome in Copaxone USers
• Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
• A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
• Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability
• A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
• Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
• Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
• Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
• Fatigue Treatment Using Provigil
• Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
• Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
• A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
• A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
• Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
• Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS
• A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
• An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
• Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
• Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
• Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
• A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
• Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
• Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
• Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
• A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
• Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis
• Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
• Efficacy and Safety of BG00012 in MS
• Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients
• AVONEX® Combination Trial - "ACT"
• Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects
• BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
• Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
• Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
• A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
• Safety of RG2077 in Patients With Multiple Sclerosis
• Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
• Treatment of Multiple Sclerosis Using Over the Counter Inosine
• A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
• Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
• Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis